Greenwich LifeSciences provides an update regarding its Form 10-K filing for the fiscal year ending December 31, 2025. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences, Inc.
97 posts
Greenwich LifeSciences, Inc.
@GreenwichLS
Greenwich LifeSciences, Inc. (GLSI) is a public clinical-stage biopharmaceutical company developing an immunotherapy to prevent breast cancer recurrences.
Stafford, TX Katılım Aralık 2020
0 Takip Edilen301 Takipçiler
Greenwich LifeSciences announces that an abstract and corresponding poster have been accepted for publication at the upcoming 2026 ASCO Annual Meeting. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences presents preliminary FLAMINGO-01 open label data published at AACR Meeting 2026. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences provides updates on its financing strategy. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences provides an update on new patent claims based on FLAMINGO-01 statistically significant open label immune response and recurrence rate data. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences announces the addition of City of Hope to FLAMINGO-01. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences provides an update on the upcoming AACR Meeting. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences provides an update showing a continued reduction in the recurrence rate in the fully enrolled open label arm of FLAMINGO-01. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences announces the use of commercially manufactured GP2 in FLAMINGO-01. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences provides an update on the increased patient screen rate in FLAMINGO-01. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences announces the acceptance of two abstracts at AACR Annual Meeting 2026. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences provides updates on the FLAMINGO-01 cash burn rate and financing strategy. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences announces that the FDA approves the use of commercially manufactured GP2 in FLAMINGO-01. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences extends lock-up of directors and officers to September 30, 2026. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences provides additional updates on FLAMINGO-01 and the Company's corporate strategy. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences announces preliminary analysis showing an 80% recurrence rate reduction in the open label arm of FLAMINGO-01. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences announces the completion of enrollment in the open label arm of FLAMINGO-01. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences provides a global update on FLAMINGO-01, screening over 1,000 patients to date. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences announces the addition of Austria to the Flamingo-01 clinical trial. | $GLSI | globenewswire.com/news-release/2…
English
Greenwich LifeSciences announces the expansion of FLAMINGO-01 clinical trial to Belgium. | $GLSI | globenewswire.com/news-release/2…
English